Monte Rosa Therapeutics (GLUE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.03
- Estimate
- -$0.20
- Surprise
- +114.9%
- Revenue (period 2026-09-30)
- $54.4M
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Monte Rosa Therapeutics (GLUE) beat the -$0.20 estimate with adjusted EPS of $0.03 — a large 114.9% upside surprise.
Coverage in the report window
- Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25 — benzinga, 2026-11-06
- Monte Rosa Therapeutics Grants Inducement Equity Awards to New Employees — fiscal.ai, 2026-11-05
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates GLUE Sell at 4.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +114.9% surprise compares with a +3.7% four-quarter average.
What argues against it
- Quality below floor (1.5 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 6.0), Material insider selling (6 sells, 4.25% of cap)
- Momentum score 2.8/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.20
- Price target
- $23.38
- Stop
- $9.49
- Upside to target
- +129.2%
- Reward-to-risk
- 11.0:1
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
GLUE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $874.5M
- P/E (fwd)
- -5.6
- 52-week range
- $9.68–$25.77
- Off 52-week high
- 60.4%
- RSI (14)
- 43
- Volume vs avg
- 0.16×
- Score today
- 4.5/10